- WuXi Biologics has started construction of a 30,000-square-metre modular Drug Product facility in Singapore’s Tuas Biomedical Park.
- The facility, built in collaboration with Pharmadule Morimatsu, is expected to be operational in 2027 and will expand the company’s global CDMO capabilities.
WuXi Biologics has commenced construction of a new modular Drug Product (DP) facility in Singapore as part of its expanding CRDMO hub in the region. The site will cover approximately 30,000 square metres and is being built in collaboration with Pharmadule Morimatsu using a modular construction strategy.
A total of 470 prefabricated components are being assembled at Morimatsu’s plant in Changshu City, China, and will be shipped to Singapore’s Tuas Biomedical Park for final installation. Once operational in 2027, the facility will be among the largest modular biologics DP facilities globally.
The new site will house advanced manufacturing lines, three pre-filled syringe (PFS) lines, and two vial lines capable of processing both liquid and lyophilised products. It will also feature centralised Quality Control (QC) and Manufacturing Science and Technology (MSAT) labs, supporting end-to-end contract manufacturing services for both clinical and commercial drug product supply.
Dr. Chris Chen, CEO of WuXi Biologics, said, “Expanding our global capacity and capabilities underscores WuXi Biologics’ commitment to enabling clients as they pursue innovation and deliver breakthroughs that benefit patients worldwide.”
The company also confirmed that the design phase has begun for a Drug Substance (DS) facility, which will form part of the same CRDMO hub. The Singapore expansion complements WuXi Biologics’ existing global network, which includes facilities across Ireland, Germany, the United States, China, and Singapore, with a planned total manufacturing capacity exceeding 500,000 litres.
